Literature DB >> 20929397

Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota.

Caroline Mitchell1, Jane Hitti, Kathleen Paul, Kathy Agnew, Susan E Cohn, Amneris E Luque, Robert Coombs.   

Abstract

We examined the relationship of proinflammatory vaginal cytokines and secretory leukocyte protease inhibitor (SLPI) with genital HIV-1 shedding after controlling for genital coinfections. Fifty-seven HIV-1-infected women in Seattle, WA (n = 38) and Rochester, NY (n = 19) were followed every 3-4 months for a total of 391 visits. At each visit, plasma and cervicovaginal lavage (CVL) were tested for HIV-1 RNA using qPCR. Vaginal samples were tested for bacterial vaginosis, yeast, hydrogen peroxide-producing Lactobacillus colonization, Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis, CMV, and HSV shedding. CVL interleukins (IL)-1β, IL-6, IL-8, and SLPI were measured using ELISA. Linear regression with generalized estimating equations examined effects of cytokine concentrations on CVL HIV-1 RNA, adjusted for plasma HIV RNA, and measured coinfections. CVL IL-1β and IL-8 were significantly associated with CVL HIV-1 RNA. This persisted after adjusting for plasma HIV-1 RNA. Higher levels of IL-1β were associated with higher concentrations of HIV-1 RNA in CVL (β = 0.25, 95% CI 0.09, 0.42), as were higher levels of IL-8 (β = 0.34, 95% CI 0.17, 0.50). Adjusting for the presence of the coinfections described, this relationship was attenuated for IL-1β (β = 0.16; 95% CI -0.01, 0.33) but still significant for IL-8 (β = 0.29; 95% CI 0.13, 0.45). The proinflammatory cytokines IL-1β and IL-8 are associated with higher cervicovaginal HIV-1 RNA concentrations, even after controlling for plasma viral load and vaginal microbial cofactors. This association suggests that there may be additional, noninfectious causes of inflammation that increase cervicovaginal HIV-1 shedding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20929397      PMCID: PMC3034096          DOI: 10.1089/aid.2010.0129

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  32 in total

1.  Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix.

Authors:  S D Lawn; S Subbarao; T C Wright; T Evans-Strickfaden; T V Ellerbrock; J L Lennox; S T Butera; C E Hart
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

Review 2.  The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis.

Authors:  Leigh F Johnson; David A Lewis
Journal:  Sex Transm Dis       Date:  2008-11       Impact factor: 2.830

3.  Genital tract leukocytes and shedding of genital HIV type 1 RNA.

Authors:  Brenna L Anderson; Chia-Ching Wang; Allison K Delong; Tao Liu; Erna Milu Kojic; Jaclynn Kurpewski; Jessica Ingersoll; Kenneth Mayer; Angela M Caliendo; Susan Cu-Uvin
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

4.  The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1.

Authors:  C C Wang; R S McClelland; M Reilly; J Overbaugh; S R Emery; K Mandaliya; B Chohan; J Ndinya-Achola; J Bwayo; J K Kreiss
Journal:  J Infect Dis       Date:  2001-02-28       Impact factor: 5.226

5.  Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women.

Authors:  S B Mostad; J K Kreiss; A J Ryncarz; J Overbaugh; K Mandaliya; B Chohan; J Ndinya-Achola; J J Bwayo; L Corey
Journal:  J Med Virol       Date:  1999-12       Impact factor: 2.327

6.  Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration.

Authors:  T C Wright; S Subbarao; T V Ellerbrock; J L Lennox; T Evans-Strickfaden; D G Smith; C E Hart
Journal:  Am J Obstet Gynecol       Date:  2001-02       Impact factor: 8.661

7.  Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women.

Authors:  Gregory T Spear; M Reza Zariffard; Hua Y Chen; Joshua J Anzinger; Kathryn Anastos; John Rusine; John Gatabazi; Audrey L French; Mardge Cohen; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2008-07       Impact factor: 2.205

8.  Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines.

Authors:  Caroline M Mitchell; Jennifer Balkus; Kathy J Agnew; Susan Cohn; Amneris Luque; Richard Lawler; Robert W Coombs; Jane E Hitti
Journal:  AIDS Res Hum Retroviruses       Date:  2008-05       Impact factor: 2.205

9.  Relation between HIV viral load and infectiousness: a model-based analysis.

Authors:  David P Wilson; Matthew G Law; Andrew E Grulich; David A Cooper; John M Kaldor
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

10.  Vaginal IL-8 levels are positively associated with Candida albicans and inversely with lactobacilli in HIV-infected women.

Authors:  Gregory T Spear; M Reza Zariffard; Mardge H Cohen; Beverly E Sha
Journal:  J Reprod Immunol       Date:  2008-02-19       Impact factor: 4.054

View more
  33 in total

Review 1.  Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.

Authors:  Michael L Freeman; Michael M Lederman; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation.

Authors:  Catherine A Blish; R Scott McClelland; Barbra A Richardson; Walter Jaoko; Kishorchandra Mandaliya; Jared M Baeten; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

3.  Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection.

Authors:  Melanie Merbah; Andrea Introini; Wendy Fitzgerald; Jean-Charles Grivel; Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

Review 4.  Microbiome in human immunodeficiency virus infection.

Authors:  January T Salas; Theresa L Chang
Journal:  Clin Lab Med       Date:  2014-09-18       Impact factor: 1.935

5.  Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding.

Authors:  Heather B Jaspan; Lenine Liebenberg; Willem Hanekom; Wendy Burgers; David Coetzee; Anna-Lise Williamson; Francesca Little; Landon Myer; Robert W Coombs; Don Sodora; Jo-Ann Passmore
Journal:  J Infect Dis       Date:  2011-09-21       Impact factor: 5.226

Review 6.  The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract.

Authors:  Paria Mirmonsef; Laurie Krass; Alan Landay; Gregory T Spear
Journal:  Curr HIV Res       Date:  2012-04       Impact factor: 1.581

7.  Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation.

Authors:  Mohak Mhatre; Thomas McAndrew; Colleen Carpenter; Robert D Burk; Mark H Einstein; Betsy C Herold
Journal:  Sex Transm Dis       Date:  2012-08       Impact factor: 2.830

8.  Persistent Mycoplasma genitalium infection of human endocervical epithelial cells elicits chronic inflammatory cytokine secretion.

Authors:  Chris L McGowin; Rochelle S Annan; Alison J Quayle; Sheila J Greene; Liang Ma; Miriam M Mancuso; David Adegboye; David H Martin
Journal:  Infect Immun       Date:  2012-08-20       Impact factor: 3.441

9.  Biomarkers of Cervical Inflammation and Immunity Associated with Cervical Shedding of HIV-1.

Authors:  Christine Mauck; Pai-Lien Chen; Charles S Morrison; Raina N Fichorova; Cynthia Kwok; Tsungai Chipato; Robert A Salata; Gustavo F Doncel
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-26       Impact factor: 2.205

Review 10.  Research gaps in defining the biological link between HIV risk and hormonal contraception.

Authors:  Kerry Murphy; Susan C Irvin; Betsy C Herold
Journal:  Am J Reprod Immunol       Date:  2014-02-19       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.